Application Data
Mouse anti-Rat C5b-9 Monoclonal Antibody | anti-C5b-9 antibody
C5b-9, Rat, mAb 2A1
Reactivity
Rat
Applications
Immunohistochemistry, Western Blot, Immunofluorescence, Flow Cytometry, Functional Assay
Purity
Protein G
Synonyms
C5b-9, Antibody; C5b-9, Rat, mAb 2A1; Membrane attack complex, MAC, TCC, Terminal Complement Complex; anti-C5b-9 antibody
Host
Mouse
Reactivity
Rat
Clonality
Monoclonal
Isotype
Mouse IgG1
Purity/Purification
Protein G
Form/Format
0.2 um filtered in PBS + 0.1% BSA + 0.02% NaN3
For unit size 0.5 mg or larger: PBS only (concentration< 0.5mg/ml)
For unit size 0.5 mg or larger: PBS only (concentration< 0.5mg/ml)
Concentration
100 ug/ml (varies by lot)
Applicable Applications for anti-C5b-9 antibody
IHC (Immunohistochemistry), WB (Western Blot), IF (Immunofluorescence), IA (Immunoassay), FCM/FACS (Flow Cytometry)
Immunogen
Rat C5b-9
Positive Control
Glomeruli of rats treated with anti-Thy-1.1 antibodies
Preparation and Storage
Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for one year.
Application Data
Application Data
IA (Immunoassay)
(IA: Immuno assay experiment with AAA77761. AAA77761 was used as a capture antibody.)
IA (Immunoassay)
(IA: Immuno assay experiment with AAA77761. AAA77761 was used as a capture antibody.)
Related Product Information for anti-C5b-9 antibody
Product Description: The monoclonal antibody 2A1 recognizes rat C5b-9. The antibody was shown to compete with antibodies to human C9 for its binding site on the C5b-9 complex, indicating that the reactive epitope is located on the C9 molecule. C5b-9 membrane attack complexes are assembled from five precursor molecules in the serum. Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 complex. The last step of C5b-9 complex formation involves polymerization of C9 which accompanies insertion of the complex into the cell membrane. During formation of C5b-8 and C9 polymerization, neoantigens are generated which are unique to the C5b-9 complex and are not present on any of the individual native complex components. The complement regulatory proteins CD59 and complement S-protein can both prevent C5b-9 insertion into the cell membrane. The formed SC5b-9 complex is unable to attach to cells and is cytolytically inactive.C5b-9 is involved in the progression of chronic proteinuric renal disease by mediating continuous tubulointerstitial damage. Early tubulointerstitial injury in the remnant kidney can be improved when C5b-9 complex forming is abrogated.
The monoclonal antibody 2A1 was raised against a rat C5b-9 neoantigen. Monoclonal antibody 2A1 can be used as a coating antibody to detect C5b-9 in plasma and urine samples.
The monoclonal antibody 2A1 was raised against a rat C5b-9 neoantigen. Monoclonal antibody 2A1 can be used as a coating antibody to detect C5b-9 in plasma and urine samples.
References
1. Schulze, M et al. Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int. 1989, 35: 60 2. Brandt, J et al. Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int. 1996, 49: 335
3. Sato, T et al.The terminal sequence of complement plays an essential role in antibody-mediated renal cell apoptosis. J Am Soc Nephrol 1999, 10: 1242
4. Duijvestijn, A. Complement activation by anti-endothelial cell antibodies in MHC-mismatched and MHC-matched heart allograft rejection: anti-MHC, but not anti non-MHC alloantibodies are effective in complement activation. Transpl. Int. 2000, 13:363
5. Yamada,K et al. Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. Kidney Intern 2001. 59:137
6. Nangaku M et al. C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys J. Am. Soc. Nephrol. 2002, 13: 928
7. Rangan GK et al. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int- 2004, 66: 1838
8. Ostendorf, T et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2006, 17: 1054
3. Sato, T et al.The terminal sequence of complement plays an essential role in antibody-mediated renal cell apoptosis. J Am Soc Nephrol 1999, 10: 1242
4. Duijvestijn, A. Complement activation by anti-endothelial cell antibodies in MHC-mismatched and MHC-matched heart allograft rejection: anti-MHC, but not anti non-MHC alloantibodies are effective in complement activation. Transpl. Int. 2000, 13:363
5. Yamada,K et al. Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. Kidney Intern 2001. 59:137
6. Nangaku M et al. C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys J. Am. Soc. Nephrol. 2002, 13: 928
7. Rangan GK et al. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int- 2004, 66: 1838
8. Ostendorf, T et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2006, 17: 1054
Similar Products
Product Notes
The C5b-9 (Catalog #AAA77761) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The C5b-9, Rat, mAb 2A1 reacts with Rat and may cross-react with other species as described in the data sheet. AAA Biotech's C5b-9 can be used in a range of immunoassay formats including, but not limited to, IHC (Immunohistochemistry), WB (Western Blot), IF (Immunofluorescence), IA (Immunoassay), FCM/FACS (Flow Cytometry). Researchers should empirically determine the suitability of the C5b-9 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "C5b-9, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.